Unacylated Ghrelin (UnAG): A New Treatment Option for Peripheral Arterial Disease?
Gabriele Togliatto, Matteo Traversa, Alberto Orsello and Maria Felice Brizzi*
Department of Medical Sciences, University of Torino, Italy
- Corresponding Author:
- Maria Felice Brizzi
Department of Medical Sciences, University of Torino
Corso Dogliotti 14, 10126, Torino, Italy
E-mail: [email protected]
Received date: March 24, 2014; Accepted date: June 26, 2014; Published date: July 20, 2014
Citation: Togliatto G, Traversa M, Orsello A, Brizzi MF (2014) Unacylated Ghrelin (UnAG): A New Treatment Option for Peripheral Arterial Disease?. J Mol Genet Med 8:108. doi: 10.4172/1747-0862.1000108
Copyright: © 2014 Brizzi MF, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
Unacylated Ghrelin (UnAG) Peripheral arterial disease (PAD) is a major clinical problem and a significant health care cost worldwide . PAD is the result of a progressive occlusion of the peripheral arteries driven by atherosclerosis . This, in turn, leads to a gradual reduction of blood supply to the limb and the occurrence of symptoms ranging from intermittent claudication to critical limb ischemia . Moreover, as PAD remains under-diagnosed for many years, muscle damage and ulceration are commonly found. PAD is a common vascular complication in diabetic individuals  and its incidence and prevalence are expected to increase due to the spread of diabetes and an aging population . In particular, diabetic patients have a high risk of developing PAD which is more severe and diffuse than in nondiabetic patients . Moreover, the presence of PAD in these patients is associated with an increased morbidity and mortality for cardiovascular diseases [1,4].